Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054869 | 1.00 | GRM5 (0.70) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL1544607 | 0.90 | GRM5 (0.72) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL4331565 | 0.90 | GRM5 (0.72) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL1848325 | 0.90 | GRM5 (0.72) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL4328931 | 0.89 | GRM5 (0.71) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL5053440 | 0.89 | GRM5 (0.71) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL29175535 | 0.86 | GRM5 (0.69) | GRM5KCNH2TP53POLBMAPT | |
| Azd2066 SCHEMBL4337705 | 0.86 | GRM5 (0.69) | GRM5KCNH2TP53POLBMAPT | |
| SCHEMBL29582474 | 0.84 | GRM5 (0.66) | GRM5KCNH2TP53MAPTNPC1 | |
| SCHEMBL1545804 | 0.83 | KCNH2 (0.83) | GRM5KCNH2TP53MAPTP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2672971-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | Pharmalundensis AB (SE) | 2013-12-18 | — | — | EP | disclosed |
| WO-2012108831-A1 | METABOTROPIC GLUTAMATE RECEPTOR GROUP I ANTAGONISTS FOR TREATMENT OF ABNORMAL UNION OF TISSUE | REDECO CHEM AB (SE) | 2012-08-16 | — | — | WO | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-7476684-B2 | Compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2009-01-13 | — | — | US | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1934209-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | Astra Zeneca AB (SE) | 2008-06-25 | — | — | EP | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-11-22 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | US | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007040982-A1 | 5- (PHENYLISOXAZOLYLETHOXY) -TRIAZOL- 3 -YL SUBSTITUTED PYRIDINE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | ASTRAZENECA AB (SE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270469-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885TP53 4844/4885 |
| US-20080227824-A1 | 5-(Phenylisoxazolylethoxy) - Triazol- 3 -Yl Substituted Pyridine Compounds for the Treatment of Neurological, Psychiatric or Pain Disorders | GRIN2C, GRIK5, GRIN3A | GRM5 13/4885KCNH2 331/4885TP53 4823/4885 |
| US-20070270468-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885TP53 4844/4885 |
| US-20070129408-A1 | New compounds for the treatment of neurological, psychiatric or pain disorders | GRIN2C, OPRL1, GRIN2A | GRM5 17/4885KCNH2 579/4885TP53 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.